Molecule News and Research

RSS

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

Scientists discover cerebrospinal fluid proteins are essential for brain building

Proteins in fluids bathing the brain are essential for building the brain, discover scientists in a report published March 10 in the journal Neuron. The finding promises to advance research related to neurological disease, cancer and stem cells.

14 Mar 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

New technique may find 'hidden' receptors in nerve cells

Scientists at The Scripps Research Institute and University of Pennsylvania have found a way to uncover potential drug targets that have so far remained hidden from researchers' view.

11 Mar 2011

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

11 Mar 2011

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients.

11 Mar 2011

Harvard, Oxford Nanopore enter exclusive agreement for graphene DNA sequencing

Oxford Nanopore Technologies Ltd today announced an exclusive agreement with Harvard University's Office of Technology Development for the development of graphene for DNA sequencing.

From Oxford Nanopore Technologies 11 Mar 2011

Eisai, Epizyme partner to develop and commercialize EZH2 epigenetic enzyme

Epizyme, Inc. announced today a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.

11 Mar 2011

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011

Wnt1 protein can improve function of endothelial progenitor cells

Circulating through the bloodstream of every human being is a rare and powerful type of cell, one that can actually create new blood vessels to bypass blockages that cause heart attacks and peripheral artery disease.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Novel sortase-based techniques allow modification of a large variety of different proteins

Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.

10 Mar 2011

Immunologists identify key cell component that triggers allergic responses to cat dander

A breakthrough by scientists at The University of Nottingham could provide hope for any allergy sufferers who have ever had to choose between their health and their household pet.

10 Mar 2011

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty life-saving therapeutics, announced today it has received an Israeli Patent for its Ultrapure Transferrin to be used in Pharmaceutical Compositions.

10 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

LRI announces 12 new research grants to drive innovation in lupus

The Lupus Research Institute today announced the award of 12 new research grants, building on its decade-long commitment to drive innovation and discover novel approaches to understand and treat one of the world's most confounding and elusive diseases - lupus.

9 Mar 2011

Study: Roundworm protein can suppress inflammation in patients with sepsis

Research by the University of Liverpool has found that systemic inflammation caused by sepsis can be suppressed by a protein which occurs naturally in a type of roundworm.

8 Mar 2011

Bristol-Myers Squibb enters strategic partnership with WuXi Pharmatech

Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.

8 Mar 2011

Discovery of potent class of anti-cancer compounds by Scripps Research and MIT scientists

Working as part of a public program to screen compounds to find potential medicines and other biologically useful molecules, scientists from The Scripps Research Institute and Massachusetts Institute of Technology (MIT) have discovered an extremely potent class of potential anti-cancer and anti-neurodegenerative disorder compounds.

8 Mar 2011

Molecule News and Research

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Scientists discover cerebrospinal fluid proteins are essential for brain building

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

New technique may find 'hidden' receptors in nerve cells

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

Harvard, Oxford Nanopore enter exclusive agreement for graphene DNA sequencing

Eisai, Epizyme partner to develop and commercialize EZH2 epigenetic enzyme

Researchers create protein molecule for new anti-inflammatory therapies

Wnt1 protein can improve function of endothelial progenitor cells

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Novel sortase-based techniques allow modification of a large variety of different proteins

Immunologists identify key cell component that triggers allergic responses to cat dander

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

LRI announces 12 new research grants to drive innovation in lupus

Study: Roundworm protein can suppress inflammation in patients with sepsis

Bristol-Myers Squibb enters strategic partnership with WuXi Pharmatech

Discovery of potent class of anti-cancer compounds by Scripps Research and MIT scientists

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News